Hypertension Clinical Trials

Find Hypertension Clinical Trials Near You

Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults aged 18 years or older

• Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines

• Followed at the study center with a diagnosis of PAH

• Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval

• Availability of analyzable clinical, imaging, and hemodynamic data

• Willingness to participate in the study and provision of written informed consent

Locations
Other Locations
Turkey
Istanbul University Cerrahpasa Institute of Cardiology
RECRUITING
Istanbul
Contact Information
Primary
Aybüke Geylan, MD
aybukegeylan@gmail.com
+905061258579
Backup
Barış Güven, MD
guvenbariss@gmail.com
+905321137507
Time Frame
Start Date: 2026-05-11
Estimated Completion Date: 2027-05
Participants
Target number of participants: 50
Treatments
Patients with Group 1 Pulmonary Arterial Hypertension
Participants are adult patients with established Group 1 pulmonary arterial hypertension (PAH) undergoing follow-up at a specialized pulmonary hypertension center.
Related Therapeutic Areas
Sponsors
Leads: Istanbul University - Cerrahpasa

This content was sourced from clinicaltrials.gov